24mm Tape Label TZ Brother for Compatible TZe-751 TZ-251 5PK 8M PT-P700 P-Touch Label Tapes & Cartridges


  1. Home
  2. 24mm Tape Label TZ Brother for Compatible TZe-751 TZ-251 5PK 8M PT-P700 P-Touch
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
5PK TZ-251 TZe-751 Compatible for Brother TZ Label Tape 24mm 8M P-Touch PT-P700
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Brand:

Unbranded

Print Technology: Thermal MPN:

TZe251 TZe451 TZe551 TZe651 TZe-751

Length: 8m(26.2') Type: Label Tape
Compatible Brand: For Brother Color:

Black on White/Red/Blue/Yellow/Green

Features: Esy peel/Water/Fade/Abrasion/Chemical Resistant Tape Width: 1-inch (24mm)
Application area: Office, Home, Hotel, Factory, Electricity, Public… Model:

TZe251 TZe451 TZe551 TZe651 TZe-751

UPC:

Does not apply

EAN:

Does not apply











published on tue nov 09 2021

24mm Tape Label TZ Brother for Compatible TZe-751 TZ-251 5PK 8M PT-P700 P-Touch Label Tapes & Cartridges

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

24mm Tape Label TZ Brother for Compatible TZe-751 TZ-251 5PK 8M PT-P700 P-Touch Label Tapes & Cartridges

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS